Free Trial
OTCMKTS:CRXM

Gene Biotherapeutics (CRXM) Stock Price, News & Analysis

Gene Biotherapeutics logo

About Gene Biotherapeutics Stock (OTCMKTS:CRXM)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

Remove Ads
Receive CRXM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRXM Stock News Headlines

Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
See More Headlines

CRXM Stock Analysis - Frequently Asked Questions

Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Isoray (ISR), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO) and Intellipharmaceutics International (IPCIF).

Company Calendar

Today
4/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:CRXM
Previous Symbol
NYSE:CXM
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (OTCMKTS:CRXM) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners